Paul Hahn, MD, on what separates practice-changing retina therapies from niche ones, plus gene therapy and home-monitoring hurdles.
Paul Hahn, MD, PhD, FASRS
Advertisement
Paul Hahn, MD, PhD, FASRS, founder of phRETINA Ophthalmology Care.
Articles by Paul Hahn, MD, PhD, FASRS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
AI Chatbots Score Below 28% on Colorectal Cancer Questions
2
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
3
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
4
5 Notable FDA Approvals From the First Half of 2026
5